Reconstructed first-round book from the research data, not a scrape of today's website. Public portfolio pages over-report winners, and this graph has the same public-data bias. Investor edges are essentially Crunchbase through late 2015, plus Y Combinator.
Research book · 3-year follow-on
Sitra Ventures vs Kairos
Not ranked
Whole-book follow-on hit rate 16.7% (1 of 6 labeled deals). 95% Wilson interval 3.0%–56.4%. Vintage-weighted base rate 42.5%. This is not a fund return.
Not ranked. A book needs at least 15 labeled deals with a vintage base rate. This one has 6.
Vs same-vintage base rate
-25.8 pp
16.7% on 6 deals vs 42.5%
Vs median VC book
-36.1 pp
16.7% on 6 deals vs 52.8%
Vs top-quartile VC
-50.3 pp
16.7% on 6 deals vs 66.9%
Vs Y Combinator
-52.0 pp
20.0% on 5 deals vs 72.0%
Ranked when at least 15 labeled deals have a vintage base rate. Rank is the average-rank percentile of shrunk excess (20 pseudo-deals at that book's vintage base rate) among eligible VC books that clear the same minimum. 100 is best. The whole book is never compared to Kairos's top-50 hit rate.
What Kairos would have said
Scores are the model’s percentile at each company’s first observed funding event, not at a later round. That matches this fund’s entry only when the fund was in the first-round syndicate. A deal is flagged when its percentile clears that vintage’s top-50 cutoff. The whole book is not compared to the top-50 hit rate.
Deals with a score
6
Mean model percentile
31
Flagged deals
0no labeled flagged deals
Companies
6 labeled follow-on deals, 0 matched without an observable label (dropped, not counted as failures).
| Company | Vintage | Follow-on | Kairos percentile | Flagged |
|---|---|---|---|---|
| AW-Energyaw-energy.com | 2004 | No | 51 | — |
| Vivoxidvivoxid.com | 2005 | No | 49 | — |
| Nexstimnexstim.com | 2007 | No | 34 | — |
| Ipsat Therapies | 2005 | Yes | 23 | — |
| FIT Biotechfitbiotech.com | 2006 | No | 20 | — |
| Savosolarsavosolar.fi | 2011 | No | 10 | — |